Multi-billion dollar deal strengthens its cancer pipeline
Thursday 04 Apr 2019 Author: Lisa-Marie Janes
AstraZeneca ( AZN ) £61.67 Loss to date: 2.1% Original entry point: Buy at £63.00, 15 November 2018 AstraZeneca’s ( AZN ) $6.9bn deal with Japan’s Daiichi Sankyo to develop and sell the latter’s breast and gastric cancer drug hasn’t gone down that well with the market – more focused on how it has done the deal rather than why. Under the deal, AstraZeneca has agreed to pay $1.35bn...